Navigation Links
Pasteuria Bioscience Taps New CEO David N. Duncan
Date:10/30/2007

ALACHUA, Fla., Oct. 30 /PRNewswire/ -- Pasteuria Bioscience, Inc. (http://www.pasteuriabio.com), a Florida biotech company developing biological control products for agriculture's largest unmet pest problem, announced today that David N. Duncan, Ph.D., has been named as the new Chief Executive Officer. Dr. Duncan has also been elected to the Company's board of directors. He succeeds Dr. Kelly Smith who will remain active with the Company as its Chief Technology Officer.

Following his formal education at Indiana State and Michigan State universities, Dr. Duncan joined Monsanto Company where he held positions in product development, marketing, government and regulatory affairs; and as both a commercial development and business unit executive. Notably, Duncan led Monsanto's turf and ornamental business and the development of Dimension(R) turf herbicide. Dimension is today one of the premier products used by turfgrass professionals and homeowners.

After retirement from Monsanto, Duncan took on the CEO role at Chlorogen, Inc. where he raised $10M from a syndicate of venture investors and proceeded to build the company into a highly regarded start-up focused on human therapeutic protein expression and production in tobacco. "I have been involved with groundbreaking technologies and trend-setting companies my entire career. Pasteuria, with its focus on a revolutionary approach to nematode control, offers the same kind of challenge and exciting opportunity to make a difference," said Duncan. "Along with our dedicated science team and the support of committed investors, I am convinced we have the talent and resources to take this technology through scale-up manufacturing, regulatory approval and a successful commercial launch. The global agriculture industry needs this technology-based solution and we intend to bring it to them."

Recent investor LSP through its BioVentures fund is also pleased to have Duncan on board at Pasteuria. "Dave's combination of past experience in product development and as a CEO for a start-up company will help Pasteuria greatly as they transition from a research to a development and production company," said Jorg Riesmeier, Partner at LSP BioVentures and Pasteuria board member.

Plant-parasitic nematodes are agriculture's largest unmet pest problem. These microscopic worms attack plant roots, causing an estimated $100 billion in worldwide crop damage annually. Pasteuria has developed a patented, cost- effective commercial scale process for the production of Pasteuria bacteria, a naturally occurring predator. These predatory microbes specifically target, infect, and kill selected nematodes-without leaving toxic crop residues. Other organisms remain unharmed, soil and water is left free of contaminants, and there are no known human exposure risks. Additionally, Pasteuria's microbes are highly durable and require no special handling or storage conditions. The company is on pace to file a submission for registration to EPA by mid-2008.

Pasteuria's investment partners include LSP BioVentures (http://www.lspvc.com), a $100 million fund focused on early to mid-staged companies in the areas of agriculture, food and nutrition, health & wellness, biofuels and related platform technologies; Advantage Capital (http://www.advantagecap.com), a venture capital and private equity firm focused on early-stage companies and other investments supporting state and local economic development; and Gordon River Capital (http://www.gulfshorecap.com), an affiliate of Florida Gulfshore Capital, a Naples, FL based private investment firm involved in the development and sale of consumer, industrial, and medical products and services.

Pasteuria Bioscience, founded in 2003, is located at the University of Florida's Sid Martin Biotechnology Incubator in Alachua, Florida, a nationally recognized bio-business development program providing facilities, equipment, and introductions to capital and business leadership in an entrepreneurial environment.


'/>"/>
SOURCE Pasteuria Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Bioscience clusters: Too many or room for more?
5. Quintessence Biosciences names new president
6. Caden Biosciences may signal critical mass
7. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
8. WARF signs licensing pact with BD Biosciences
9. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
10. Bioscience beats beer
11. State awards QRG Biosciences development grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):